2026– date –
-
From Beginner to Expert | Bispecific Antibody Drug Series B5: How Should We Think About Clinical Development Strategy and Indication Expansion?
Bispecific antibody drugs are a modality in which theoretical appeal alone is not enough; where and how clinical development begins is critically important. As we have seen from A1 through A5 and B1 through B4, this field is shaped by st... -
From Beginner to Expert | Bispecific Antibody Drug Series A5: Where Do Bispecific Antibody Drugs Sit Within the Overall Landscape of Cancer Therapy?
Bispecific antibody drugs have gained a strong presence within cancer therapy over the past several years. However, to truly understand this field, it is not enough to look at bispecific antibody drugs in isolation. What matters is to pl... -
From Beginner to Expert | Bispecific Antibody Drug Series B4: How Should We Think About Toxicity, PK/PD, and Development Bottlenecks?
Bispecific antibody drugs are a modality that often looks highly attractive in theory. Because they can handle two targets within a single molecule, they can aim for pharmacological effects that are difficult to achieve with single-targe... -
From Beginner to Expert | Bispecific Antibody Drug Series A4: Why Do Adverse Effects Occur? Understanding the Balance Between Efficacy and Safety
Bispecific antibody drugs are a modality with enormous promise in cancer therapy. As we have seen from A1 through B3, the strength of this field lies in the ability of a single molecule to engage two targets or conditions and achieve pha... -
From Beginner to Expert | Bispecific Antibody Drug Series B3: How Differences in Modality Shape Pharmacological Properties
When we look at bispecific antibody drugs, it becomes clear that even though they are grouped under the same label, they can behave very differently as actual medicines. One molecule may show very strong cell-bridging activity while stru... -
From Beginner to Expert | Bispecific Antibody Drug Series A3: What Types Are There? Classification and the Overall Landscape of Bispecific Antibody Drugs
Bispecific antibody drugs are often discussed as if they were a single technological field. In reality, however, their internal diversity is substantial. As we saw in A1, the essence of bispecific antibody drugs is to connect two targets... -
From Beginner to Expert | Bispecific Antibody Drug Series B2: What Determines Target Design and the Optimization of Mechanism of Action?
When people think about the design of bispecific antibody drugs, they often focus first on which targets should be combined. That is natural, because the value of bispecific antibody drugs arises from handling two targets at the same tim... -
From Beginner to Expert | Bispecific Antibody Drug Series A2: How Do Bispecific Antibody Drugs Work? A Clear Guide to Their Mechanisms of Action
One of the reasons bispecific antibody drugs attract so much attention is that they can bind two targets within a single molecule. However, as we saw in A1 and B1, what truly matters is not simply the fact that they can bind two things. ... -
From Beginner to Expert | Bispecific Antibody Drug Series B1: Comparing Structural Designs and Their Impact on Therapeutic Effects
One of the first major hurdles in understanding bispecific antibody drugs is recognizing that the single term “bispecific antibody drugs” actually includes fundamentally different molecular design concepts. In A1, we described bispecific... -
From Beginner to Expert | Bispecific Antibody Drug Series A1: What Are Bispecific Antibody Drugs? A Thorough Introduction from the Basics
Bispecific antibody drugs are now one of the most important themes in the evolution of cancer therapy and antibody therapeutics. Over the past several years, they have rapidly increased in prominence. In hematologic malignancies, they ar... -
From Beginner to Expert | Bispecific Antibody Drug Series A0: What This Series Will Help You Understand
Bispecific antibody drugs have become one of the most prominent areas in cancer therapy over the past several years. If we only follow headlines, we often see striking phrases such as “a new antibody that brings T cells to cancer,” “a ne... -
Frontier of Therapy Series: Training Immunity to Fight Cancer | The Full Picture of CAR-T (From Beginner to Expert): Complete Index and Series Overview
This article serves as the complete index page for the CAR-T series now that the series has been completed. It is designed as a single entry point that allows readers to see the full picture, from the basics to expert-level implementatio... -
Frontier of Therapy Series: Training Immunity to Fight Cancer: The Full Picture of CAR-T (From Beginner to Expert) B6: What Defines a Winning Commercialization Strategy for CAR-T? Practical Implementation Across COGS, Supply Chain, Site Requirements, and Regulation
In A5 and B5, we explored how in vivo CAR-T is emerging not simply as a novel scientific idea, but as a possible answer to the structural problems of manufacturing, logistics, and access. In A6, we translated that trend into the patient ... -
Frontier of Therapy Series: Training Immunity to Fight Cancer: The Full Picture of CAR-T (From Beginner to Expert) A6: Why Is CAR-T So Expensive? The Reality of Manufacturing, Patient Access, and the Future Shaped by Next-Generation Technologies
CAR-T therapy is one of the cancer treatments that has attracted particularly strong expectations in recent years. In fact, in relapsed or refractory hematologic malignancies, it can produce deep responses that were difficult to achieve ... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B5: Implementing In Vivo CAR (Delivery × Control × Safety × CMC/Reg) — The Real Hard Problems of “Making CAR Cells Inside the Body” [Expert]
If you want the beginner version first:→ A5: What is in vivo CAR? “Making CAR cells inside the body” explained simply “In Vivo CAR Implementation Stack” Delivery (tLNP/vector, targeting, biodistribution) Control (dose-dependent, repeat d... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A5: What Is In Vivo CAR? “Making CAR Cells Inside the Body” Explained Simply [Beginner]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A4: Why CAR-T Is Expanding Beyond Cancer (Autoimmunity as an “Immune Reset” Concept) “In vivo CAR at a glance: dose → in-body CAR expression → trans... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B4: Autoimmune CAR-T Frontier (Design Logic, Disease Buckets, and Company Landscape) [Expert]
Prefer the overview first?→ A4: Why CAR-T expands beyond cancer (autoimmunity as “reset”) “Autoimmune CAR: Reset Toolkit (Target × Durability × Safety)” Executive summary Autoimmune CAR-T is shifting the goal from “killing tumor cells” t... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A4: Why CAR-T Is Expanding Beyond Cancer (Autoimmunity as an “Immune Reset” Concept) [Beginner]
New here?→ A0: What is CAR-T therapy? The big picture + index (Coming from solid tumors?)→ A3: Why solid tumors are hard for CAR-T→ B3: Solid-tumor CAR-T design toolkit “From Suppression to Reset: Why CAR-T Moves Beyond Cancer” The short... -
Oncology Drug Approval News Flash FDA approves nivolumab (Opdivo) with AVD chemotherapy for previously untreated advanced classical Hodgkin lymphoma (and converts prior accelerated approvals in relapsed/refractory cHL to traditional approval)
On March 20, 2026, the U.S. FDA approved nivolumab (Opdivo) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adults and pediatric patients aged 12 years and older with previously untreated, Stage III or IV classica... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B3: How Solid-Tumor CAR-T Tries to Win (Next-Gen Design: Multi-Target, Logic Gates, Armoring, Local Delivery) [Expert]
Prefer the beginner overview first?→ A3: Why solid tumors are hard for CAR-T (the 3 barriers) “Solid-Tumor CAR-T Design Toolkit to Beat 3 Barriers” (Trafficking / TME resistance / Target & safety) Executive summary Solid-tumor CAR-T ...
